Reference:
Rutenberg, D., & Zhang, Y. (2021). The clot thickens: Does the Johnson & Johnson COVID-19 vaccine increase the risk of thrombus in a hypercoagulable state? Chest, 2195. https://doi.org/10.1016/j.chest.2021.07.1937
Summary:
Since January 2020, Elsevier has provided a COVID-19 resource centre offering free access to information on the novel coronavirus. The resource centre allows unrestricted sharing of related research. The article discusses a case involving a 54-year-old woman with antiphospholipid syndrome (APS) who developed acute deep venous thrombosis (DVT) after receiving the Johnson & Johnson (J&J) vaccine. This case follows reports from the CDC and FDA linking the J&J vaccine to cerebral venous sinus thrombosis. The patient, already in a hypercoagulable state due to APS, experienced complications after vaccination. Despite being on warfarin, she developed bilateral swelling and calf pain, and subsequent imaging confirmed DVT. Given the potential for a heparin-induced thrombocytopenia-like state caused by the J&J vaccine, the authors recommend caution in administering this vaccine to patients with known hypercoagulable conditions, especially amidst severe COVID-19.